110 related articles for article (PubMed ID: 36634548)
1. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira JP; Cleland JGF; Girerd N; Pellicori P; Hazebroek MR; Verdonschot J; Collier TJ; Petutschnigg J; Clark AL; Staessen JA; Heymans S; Rossignol P; Zannad F
Am J Cardiol; 2023 Mar; 191():39-42. PubMed ID: 36634548
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
[TBL] [Abstract][Full Text] [Related]
4. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
5. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
6. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
[TBL] [Abstract][Full Text] [Related]
7. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.
Selvaraj S; Ilkhanoff L; Burke MA; Freed BH; Lang RM; Martinez EE; Shah SJ
J Am Soc Echocardiogr; 2014 Jan; 27(1):74-82.e2. PubMed ID: 24075945
[TBL] [Abstract][Full Text] [Related]
8. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
10. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
11. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S; López B; Ferreira JP; Girerd N; Bozec E; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Moreno MU; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Cleland JGF; Zannad F; Díez J; González A;
Eur J Heart Fail; 2022 Feb; 24(2):321-331. PubMed ID: 34841615
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Xiang Y; Shi W; Li Z; Yang Y; Wang SY; Xiang R; Feng P; Wen L; Huang W
Medicine (Baltimore); 2019 Mar; 98(13):e14967. PubMed ID: 30921200
[TBL] [Abstract][Full Text] [Related]
14. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
15. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.
Santos AB; Kraigher-Krainer E; Bello N; Claggett B; Zile MR; Pieske B; Voors AA; McMurray JJ; Packer M; Bransford T; Lefkowitz M; Shah AM; Solomon SD
Eur Heart J; 2014 Jan; 35(1):42-7. PubMed ID: 24164863
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
17. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
[TBL] [Abstract][Full Text] [Related]
19. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular diastolic and systolic dyssynchrony and dysfunction in heart failure with preserved ejection fraction and a narrow QRS complex.
Liu S; Guan Z; Jin X; Meng P; Wang Y; Zheng X; Jia D; Ma C; Yang J
Int J Med Sci; 2018; 15(2):108-114. PubMed ID: 29333094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
